Grace Therapeutics Net Income Over Time
| GRCE Stock | 3.70 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Grace Therapeutics Performance and Grace Therapeutics Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics' market value can be influenced by many factors that don't directly affect Grace Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Grace Therapeutics and related stocks such as LAVA Therapeutics, Tvardi Therapeutics, and Actinium Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVRD | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (88.4 M) | (85.5 M) | (118.5 M) | (70.9 M) | (63.8 M) | (67 M) |
| ATNM | (18.4 K) | 10.3 K | (8.4 M) | (10.8 M) | (24.7 M) | (21 M) | (24.3 M) | (26.6 M) | (23.7 M) | (21.9 M) | (22.2 M) | (24.8 M) | (33 M) | (48.8 M) | (38.2 M) | (34.4 M) | (32.7 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| CALC | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (37 M) | (27.5 M) | (35.8 M) | (7.8 M) | (34.4 M) | (13.7 M) | (15.8 M) | (16.5 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
| LTRN | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (2.4 M) | (5.9 M) | (12.4 M) | (14.3 M) | (16 M) | (20.8 M) | (18.7 M) | (17.8 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| RNXT | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (6.3 M) | (9.8 M) | (10.2 M) | (8.8 M) | (7.9 M) | (8.3 M) |
| ABVC | (20 K) | (1.2 M) | (24.1 K) | (24.1 K) | (24.1 K) | (32.3 K) | (11 M) | (4.2 M) | (5.6 M) | (3.6 M) | (9.8 M) | (12.8 M) | (16.4 M) | (7.8 M) | (4.9 M) | (4.4 M) | (4.6 M) |
Grace Therapeutics and related stocks such as LAVA Therapeutics, Tvardi Therapeutics, and Actinium Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Grace Therapeutics financial statement analysis. It represents the amount of money remaining after all of Grace Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Grace Therapeutics | GRCE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 103 Carnegie Center, |
| Exchange | NASDAQ Exchange |
null 3.7
Check out Grace Therapeutics Performance and Grace Therapeutics Correlation. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Grace Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.